|Mr. Jerome D. Jabbour J.D.||Co-Founder, CEO, Pres & Director||450.46k||N/A||1974|
|Dr. Raphael J. Mannino||Sr. VP & Chief Scientific Officer||240k||N/A||1947|
|Mr. Keith A. Kucinski CPA, M.B.A.||Chief Financial Officer||N/A||N/A||1970|
|Dr. Theresa Matkovits||Chief Devel. Officer||N/A||N/A||1967|
|Mr. Frank Calamusa||Exec. Director and Head of Manufacturing & Supply Chain||N/A||N/A||N/A|
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.
Matinas BioPharma Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.